Capecitabine Combined With Lenvatinib & Tislelizumab as Adjuvant Treatment

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05489211` - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)	Phase 2
Withdrawn	`NCT03110510` - FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study	Phase 2
Completed	`NCT05116891` - A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors	Phase 1/Phase 2
Completed	`NCT00380588` - Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer	Phase 2
Terminated	`NCT00090025` - XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors	Phase 3
Terminated	`NCT04066491` - Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC	Phase 2/Phase 3
Recruiting	`NCT05998447` - GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer	Phase 2
Recruiting	`NCT03718897` - Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome Sequencing
Recruiting	`NCT05056116` - A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer	N/A
Recruiting	`NCT04692051` - A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer	Phase 2
Terminated	`NCT04057365` - Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)	Phase 2
Recruiting	`NCT04907643` - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes	N/A
Completed	`NCT02829918` - Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers	Phase 2
Recruiting	`NCT04584996` - CIRcular and Non-coding RNAs as Clinically USeful Biomarkers in Pancreaticobiliary Cancers
Completed	`NCT02579616` - Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy	Phase 2
Recruiting	`NCT05052099` - Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer	Phase 1/Phase 2
Recruiting	`NCT01494363` - Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer	Phase 2
Completed	`NCT00753675` - Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer	Phase 2
Terminated	`NCT00630890` - Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)	Phase 1
Recruiting	`NCT04445532` - Hepatobiliary Tumors Tissue Samples Acquisition

NCT number	NCT05254847
Study type	Interventional
Source	Fudan University
Contact	Lu Wang, M.D
Phone	+86-18121299357
Email	w.lr@hotmail.com
Status	Recruiting
Phase	Phase 2
Start date	December 30, 2021
Completion date	December 2024

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms